RECURRENT CANCER: Unique Treatment Guidance After Cancer Returns. Webinar recording now available.

Recurrent Cancer: Unique Treatment Guidance After Cancer Returns—Webinar Recording Now Available

Cancer Commons’ most recent webinar, Recurrent Cancer: Unique Treatment Guidance After Cancer Returns, was held virtually June 14, 2023. During the presentation, Dennis Watson, VP of Business Development of Travera, provided viewers with information and updates on a cancer therapy guidance test designed to predict which cancer drugs are most likely to be effective for individual cancer patients.

Travera’s unique technology now applies to many cancers (common and rare tumor types), and the organization is working with numerous groups to build specific databases in ovarian, lung, colon, and pancreatic cancers.

Cancer Commons is partnering with Travera with the shared goal of helping late-stage cancer patients who are running out of therapeutic options and time. This collaboration allows us to offer patients who meet specific criteria access to this technology at NO COST, through Cancer Commons.

A complete recording of the webinar is available here. If you have questions after viewing, please feel to email Cancer Commons at